

HETEROCYCLES, Vol. 82, No. 2, 2011, pp. 1345 - 1357. © The Japan Institute of Heterocyclic Chemistry
Received, 1st July, 2010, Accepted, 12th August, 2010, Published online, 13th August, 2010
DOI: 10.3987/COM-10-S(E)85

DESIGN AND SYNTHESIS OF TELOMESTATIN DERIVATIVES CONTAINING METHYL OXAZOLE AND THEIR G-QUADRUPLEX STABILIZING ACTIVITIES†

Satoki Majima,¹ Masayuki Tera,¹ Keisuke Iida,¹ Kazuo Shin-ya,² and Kazuo Nagasawa^{1*}

¹Department of Biotechnology and Life Science Faculty of Technology, Tokyo University of Agriculture and Technology (TUAT), Koganei, Tokyo 184-8588, Japan

²Biological Information Research Center, National Institute of Advanced Industrial Science and Technology, Koto-ku, Tokyo 135-0064, Japan

Abstract – Telomestatin derivatives of L2A2-6M(2)OTD (**3b**) and L2A2-6M(4)OTD (**3c**), which have a macrocyclic hexaoxazole skeleton (6OTD) containing bis- and tetra-methyl oxazoles, were synthesized as a novel G-quadruplex ligand. This new class of “methyl oxazole containing” ligands was revealed to stabilize various G-quadruplex forming oligonucleotides more potently than “no methyl oxazole containing” L2A2-6OTD (**3a**).

INTRODUCTION

Guanine-rich DNA sequences can adopt a specific secondary structure called G-quadruplexes,¹ which exist in telomeric DNA sequences² as well as in promoter regions of some oncogenes in vitro. In telomeric DNA sequences, G-quadruplex structures not only inhibit telomerase activity, but also dissociate the telomere related proteins including TRF2³ and Pot1⁴ from 3'-overhang chromosomes and thus induce certain cancer cell lines into apoptosis. On the other hand, guanine-rich base sequences in the promoter region of *c-kit*,⁵ *bcl-2*⁶ and *c-myc*⁷ (involved in cell cycle and apoptosis) fold G-quadruplex structures, and suppress the transcriptional level of their mRNA. Thus, a stabilization of the G-quadruplex is recognized as one of the promising approaches for cancer treatments, and a number of small compounds for stabilizing G-quadruplex structures (G-quadruplex ligands) have been developed.⁸ In 2001, telomestatin (**1**) was reported as one of the most potent G-quadruplex stabilizing ligands by Seto

and Shin-ya.⁹ Telomestatin (**1**) binds to the G-quadruplex in telomere with an end-stacking mode and shows potent telomerase inhibitory activity. Over the past decade, telomestatin (**1**) has widely been applied to the discovery of telomeric G-quadruplex functions.¹⁰ Recently, we have designed and synthesized macrocyclic hexaoxazoles of 6OTDs (**2**) as a G-quadruplex ligand.¹¹ The 6OTD (**2**) has the same size and similar planarity with **1**, and believed to end-stack with a G-quartet through the π - π interaction. The macrocyclic oxazole structure in **1** and **2** contributes to stacking with a G-quartet, however, the effects of characteristic “methyl oxazole” moiety in **1** (at C6 and C9) has not gained much attention. In this paper, we describe the synthesis of L2A2-6M(2)OTD (**3b**) and L2A2-6M(4)OTD (**3c**) containing bis- and tetra- “methyl oxazoles”, respectively, inspired from the skeleton of **1** (Figure 1). Furthermore, the stabilizing ability of the G-quadruplexes by these new ligands was evaluated by fluorescence resonance energy transfer (FRET) melting assays.¹²





Figure 1. Structure of telomestatin (**1**) and its analogue of macrocyclic hexaoxazoles (**2**, **3a-c**)


RESULTS AND DISCUSSION

A novel class of 6OTD, i.e., L2A2-6M(2)OTD (**3b**) and L2A2-6M(4)OTD (**3c**), was synthesized from oxazoles **4**^{9b} and **6**^{11a} (Scheme 1). Deprotection of *N,O*-acetonide and the Boc group in **4** was employed with 4 M HCl to give amine **5**. Methyl ester of **6** was hydrolyzed with lithium hydroxide to give carboxylic acid **7**. Then, the amine **5** was reacted with the carboxylic acid **7** in the presence of 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMT-MM)¹³ and *N*-methylmorpholine (NMM) to give β -hydroxy amide **8** in 85% from **6**. Cyclodehydration of **8** with diethylaminosulfurtrifluoride (DAST)¹⁴ followed by oxazole formation with bromotrichloromethane in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU)¹⁵ gave trioxazole **9a** in 43% from **8**.

Hydrolysis of the methyl ester **9a** was conducted with lithium hydroxide to give carboxylic acid **10**, which was subsequently reacted with amine **11b** obtained from **9b**^{11b} to give **12b** by using DMT-MM and NMM in 68% yield from **9a**. Deprotection of the Cbz group in **12b** followed by hydrolysis of methyl



Scheme 1. Synthesis of trioxazole **9a**



Scheme 2. Synthesis of L2A2-6M(2)OTD (**3b**) and L2A2-6M(4)OTD (**3c**).

ester gave amino acid **13b**, which was further subjected to macrocyclization using diphenylphosphoryl azide (DPPA) and *Eti*-Pr₂N in the presence of 4-dimethylaminopyridine (DMAP) under high dilution conditions (3 mM) in CH₂Cl₂-DMF (2:1) to give **14b** in 40% yield from **12b**. After conversion of the Boc group in **14b** into amine, the resulting amine **15b** was reacted with acetic anhydride to give L2A2-6M(2)OTD (**3b**) in 78% yield from **14b**. A tetra-methyl oxazole derivative of L2A2-6M(4)OTD (**3c**) was also synthesized from **9a** and **11a** with a similarity to **3b** via **12a**, **13a**, and **14a**.

The G-quadruplex stabilizing ability of L2A2-6M(2)OTD (**3b**) and L2A2-6M(4)OTD (**3c**) was examined by FRET melting assays.¹⁶ In this assay, a ligand-induced stabilization of a folded G-quadruplex is evaluated by an incremental measurement of the melting temperature as ΔT_m . The ΔT_m values of the four kinds of (GFOs, 0.2 μ M) in the presence of **3a-c** at a concentration of 2 μ M are summarized in Table 1. The ΔT_m value of telo21 in the presence of **3a-c** were 11.7, 14.0, 16.7 °C, respectively i.e., **3c** showed most potent G-quadruplex stabilizing activity among them. The other GFOs of kit22, bcl27 and myc22 showed similar tendency with these ligands. Thus, it was revealed that with a higher increment of “methyl-oxazole” moieties in macrocyclic hexaoxazole, G-quadruplex stabilizing activity was increased. Thus, incorporation of the “methyl oxazoles” into a macrocyclic skeleton in 6OTD was realized to be an effective strategy on augmenting the interaction with the G-quadruplex. Furthermore, no significant interactions between the double-stranded DNA of ds-26 and **3a-c** were observed even at high concentrations (Table 1 and Figure 2). Thus, **3b** and **3c** are selective ligands for GFOs likewise **3a**.

Table 1. ΔT_m (°C) by FRET melting assays

Ligand	ΔT_m in 2 μ M / °C				
	telo21	kit22	bcl27	myc22	ds26
3a *	11.7	14.7	10.0	10.3	0.0
3b	14.0	17.7	12.0	12.3	0.0
3c *	16.7	19.3	14.3	13.0	0.0

The ΔT_m values are an average of three independent measurements.

*In the case of all GFOs, **3a** and **3c** showed significant differences regarding the activity to stabilize G-quadruplex structures (*P*-value < 0.025).




Figure 2. ΔT_m values of (a) telo21, (b) kit22, (c) bcl27 and (d) myc22 (0.2 μM) obtained by FRET melting assays in the presence of 60 mM KCl and various concentrations of **3a-c**. All ΔT_m values were obtained by means of triplicate assay and error bars indicate \pm standard deviations.

In conclusion, we report a synthesis of a novel G-quadruplex ligand of L2A2-6M(2)OTD (**3b**) and L2A2-6M(4)OTD (**3c**), a macrocyclic polyoxazole containing methyl oxazoles. It was revealed that the “methyl oxazole” moiety in 6M(2)OTD and 6M(4)OTD has an effect on the stabilizing activity for G-quadruplexes.

EXPERIMENTAL

General

Flash chromatography was performed on silica gel 60 (spherical size 0.040~0.100 mm; Kanto). Optical rotations were measured on a JASCO P 2200 polarimeter, using the sodium D line. ^1H NMR and ^{13}C NMR spectra were recorded on JEOL JNM-ECX 300, 400 and 500. The spectra are referenced internally according to residual solvent signals of CDCl_3 (^1H NMR; $\delta = 7.26$ ppm, ^{13}C NMR; $\delta = 77.0$ ppm), CD_3OD (^1H NMR; $\delta = 3.30$ ppm, ^{13}C NMR; $\delta = 49.0$ ppm) $\text{DMSO}-d_6$ (^1H NMR; $\delta = 2.50$ ppm, ^{13}C NMR; $\delta = 39.5$ ppm). Data for ^1H NMR are recorded as follows: chemical shift ($\delta =$ ppm) multiplicity (s, singlet; d doublet; t, triplet; m, multiplet; br, broad), integration, coupling constant (Hz).

Mass spectra were recorded on JEOL JMS-T100X spectrometer with ESI-MS mode using method as solvent. All oligonucleotides purified were obtained from Sigma Genosys and dissolved in double-distilled water to be used without further purification. FRET melting assays were made with an excitation wavelength of 470-505 nm and a detection wavelength of 523-543 nm using The DNA Engine Opticon 2-Real-Time Cycler PCR detection system (Bio-Rad).

Synthesis of 5: To a solution of **4** (3.4 g, 9.9 mmol) in dioxane (100 mL) was added 12 M HCl (33 mL), and the mixture was stirred for 20 min at rt. The reaction mixture was concentrated *in vacuo* to give **5**, which was used without further purification for the synthesis of **8**.

Synthesis of 7: To a solution of **6** (3.8 g, 8.0 mmol) in THF-H₂O (3:1, 80 mL) was added lithium hydroxide (662 mg, 15.8 mmol) at rt. After stirring at rt for 4 h, to the reaction mixture was added 1 M HCl. The resultant mixture was concentrated *in vacuo* to give **7**, which was used without further purification for the synthesis of **8**.

Synthesis of 8: To a solution of carboxylic acid **7** in THF-H₂O (3:1, 160 mL) was added amine **5**, NMM (1.75 mL, 16 mmol) and DMT-MM (3.2 g, 11.8 mmol), and the mixture was stirred at rt for 14 h. To the reaction mixture was added EtOAc, and the organics were washed with sat-NaHCO₃, 1 M HCl and brine. The organic layer was dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified on silica gel (hexane-EtOAc = 1:2) to give peptide **8** (4.4 g, 85%, 2 steps from **6**). Spectral data for **8**: $[\alpha]_D^{25}$ -32.3 (*c* 1.1, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 8.19 (s, 1H), 7.70 (m, 1H), 7.34 (m, 5H), 5.48 (s, 2H), 5.30 (δ, *J* = 6.4 Hz, 1H), 5.11 (s, 2H), 4.87 (br, 1H), 4.56 (br, 2H), 3.92 (s, 3H), 3.09 (br, 2H), 2.59 (s, 3H), 1.91-1.74 (m, 4H), 1.48-1.41 (m, 13H), 1.28 (d, *J* = 6.4 Hz); ¹³C NMR (400 MHz, CDCl₃) δ 163.7, 162.1, 161.3, 160.8, 156.1, 155.8, 153.9, 144.2, 136.1, 133.0, 128.4, 128.1, 79.1, 77.2, 67.7, 67.0, 52.2, 48.9, 40.0, 33.3, 29.3, 28.3, 22.4, 19.3, 11.6; HRMS (ESI, M+Na) calcd for C₃₁H₄₁N₅O₁₀Na 666.2751, found 666.2759.

Synthesis of 9a: To a solution of peptide **8** (4.3g, 6.7 mmol) in CH₂Cl₂ (150 mL) was added DAST (0.87 mL, 6.6 mmol) in the presence of Na₂CO₃ (698 mg, 6.6 mmol) and the reaction mixture was stirred at 0 °C under N₂ for 30 min. To the reaction mixture was added H₂O, and organic layer was extracted with CH₂Cl₂. The extracts were washed with H₂O and brine, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified on silica gel (hexane-EtOAc = 1:2) to give oxazoline (3.5 g, 83%). The oxazoline was dissolved in CH₂Cl₂ (80 mL), and BrCCl₃ (1.10 mL, 11.2 mmol) and DBU (1.67mL, 11.2 mmol) was added to the solution. The resulting mixture was stirred at 0 °C for 18 h. To the

reaction mixture was added 1 M HCl, and organic layer was extracted with CH_2Cl_2 . The extracts were washed with H_2O and brine, dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was purified on silica gel (hexane-EtOAc = 1:1) to give **9a** (1.9 g, 43%, in 2 steps from **8**). Spectral data for **9a**: $[\alpha]_{\text{D}}^{25}$ -26.7 (*c* 1.35, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 7.35 (m, 5H), 5.52 (d, *J* = 8.3 Hz, 1H), 5.12 (s, 2H), 4.96 (br, 1H), 4.56 (br, 1H), 3.93 (s, 3H), 3.08 (br, 2H), 2.79 (s, 3H), 2.70 (s, 3H), 2.00-1.85 (m, 2H), 1.50-1.35 (m, 13H); ^{13}C NMR (500 MHz, CDCl_3) δ 162.7, 161.5, 156.6, 156.0, 155.7, 154.7, 150.9, 150.6, 143.3, 136.1, 134.1, 128.4, 128.0, 125.4, 124.5, 79.0, 67.0, 52.1, 49.2, 39.9, 33.6, 29.4, 28.3, 22.3, 11.8, 11.7; HRMS (ESI, M+Na) calcd for $\text{C}_{31}\text{H}_{37}\text{N}_5\text{O}_9\text{Na}$ 646.2489, found 646.2469.

Synthesis of **12b**: To a solution of **9a** (840 mg, 1.4 mmol) in THF- H_2O (3:1, 120 mL) was added lithium hydroxide (122 mg, 2.9 mmol) at rt, and the resulting mixture was stirred for 30 min. To the reaction mixture was added 1 M HCl, and resultant was concentrated *in vacuo* to give carboxylic acid **10**, which was used without further purification. To a solution of **9b** (950 mg, 1.5 mmol) in MeOH-THF (1:1, 100 mL) was added 20% $\text{Pd}(\text{OH})_2/\text{C}$ (190 mg), and the mixture was stirred at rt for 1 h under an atmosphere of hydrogen (balloon). The reaction mixture was diluted with MeOH and filtered through a pad of celite. The organics were concentrated *in vacuo* to give amine **11b**, which was used without further purification. To a solution of carboxylic acid **10** in THF- H_2O (3:1, 100 mL) was added amine **11b**, NMM (0.33 mL, 3.0 mmol) and DMT-MM (410 mg, 2.3 mmol), and the mixture was stirred at rt for 7 h. The reaction mixture was concentrated *in vacuo*, and the resulting mixture was extracted with EtOAc. The organic layer was washed with 1 M HCl, sat- NaHCO_3 , and brine, dried over MgSO_4 , filtered and concentrated *in vacuo*. The residue was purified on silica gel (hexane-EtOAc = 1:4) to give bis-trioxazole **12b** (1.0 g, 68%, 3 steps). Spectral data for **12b**: $[\alpha]_{\text{D}}^{25}$ +6.8 (*c* 1.4, CHCl_3); ^1H NMR (300 MHz, CDCl_3) δ 8.34 (s, 2H), 8.29 (s, 1H), 8.28 (s, 1H), 7.50 (d, *J* = 9.2 Hz, 1H), 7.50 (m, 5H), 5.57 (br, 1H), 5.43 (m, 1H), 5.12 (s, 2H), 5.03 (br, 1H), 4.57 (br, 2H), 3.93 (s, 3H), 3.10 (br, 4H), 2.80 (s, 3H), 2.72 (s, 3H), 2.18-1.71 (m, 4H), 1.72-1.41 (m, 26H); ^{13}C NMR (400 MHz, CDCl_3) δ 165.5, 161.9, 161.5, 159.6, 156.7, 156.2, 156.0, 155.9, 155.8, 154.7, 154.4, 151.0, 150.8, 143.4, 141.6, 139.6, 139.1, 136.7, 136.0, 134.1, 130.8, 129.6, 128.4, 128.1, 125.4, 124.6, 79.1, 79.0, 67.2, 52.1, 49.3, 46.7, 40.2, 39.8, 33.6, 33.5, 29.5, 29.4, 28.3, 22.7, 22.3, 11.8, 11.8; HRMS (ESI, M+Na) calcd for $\text{C}_{51}\text{H}_{60}\text{N}_{10}\text{O}_{15}\text{Na}$ 1075.4137, found 1075.4151.

Synthesis of **12a**: To a solution of **9a** (850 mg, 1.4 mmol) in THF- H_2O (3:1, 100 mL) was added lithium hydroxide (120 mg, 2.8 mmol) at rt, and the resulting mixture was stirred for 1 h. To the reaction mixture was added 1 M HCl, and resultant was concentrated *in vacuo* to give carboxylic acid **10**, which was used without further purification. To a solution of **9a** (1.1 g, 1.9 mmol) in MeOH-THF (1:1, 100

mL) was added Pd(OH)₂/C (190 mg), and the mixture was stirred at room temperature for 1 h under an atmosphere of hydrogen (balloon). The reaction mixture was diluted with MeOH and filtered through a pad of celite. The filtrate was concentrated *in vacuo* to give amine **11a**, which was used without further purification. To a solution of carboxylic acid **10** in THF-H₂O (3:1, 100 mL) was added amine **11a**, NMM (300 μ L, 2.8 mmol) and DMT-MM (575 mg, 2.1 mmol), and the mixture was stirred at rt for 17 h. The reaction mixture was concentrated *in vacuo* and the resulting mixture was extracted with EtOAc. The organic layer was washed with 1 M HCl and H₂O, dried over MgSO₄, filtered and concentrated *in vacuo*. The residue was purified on silica gel (CHCl₃-EtOAc = 1:1) to give bis-trioxazole **12a** (1.5 g, 95%, 3 steps). Spectral data for **12a**: [α]_D²⁵ +3.7 (*c* 1.8, CHCl₃); ¹H NMR (400 Mz, CD₃Cl) δ 8.29 (s, 1H), 8.27 (s, 1H), 7.48 (d, *J* = 9.2 Hz, 1H), 7.34 (m, 5H), 5.52 (d, *J* = 8.7 Hz, 1H), 5.43 (m, 1H), 5.12 (s, 2H), 4.96 (br, 1H), 4.56 (br, 2H), 3.93 (s, 3H), 3.10 (br, 4H), 2.79 (s, 3H), 2.78 (s, 3H), 2.72 (s, 3H), 2.70 (s, 3H), 2.17-1.84 (m, 4H), 1.50-1.40 (m, 26H); ¹³C NMR (400 MHz, CDCl₃) δ 172.1, 167.6, 162.8, 162.6, 162.1, 161.5, 160.0, 156.7, 156.0, 155.9, 155.8, 154.9, 154.7, 150.9, 150.8, 150.6, 143.4, 141.1, 136.4, 136.1, 134.1, 128.4, 128.1, 125.4, 124.6, 124.4, 79.1, 67.4, 52.1, 49.2, 48.9, 46.6, 40.1, 39.9, 33.7, 33.5, 29.6, 29.5, 28.3, 22.8, 22.4, 14.0, 11.8; HRMS (ESI, M+Na) calcd for C₅₃H₆₄N₁₀O₁₅Na 1103.4450, found 1103.4463.

Synthesis of 14b: To a solution of bis-trioxazole **12b** (580 mg, 0.55 mmol) in THF-H₂O (3:1, 60 mL) was added lithium hydroxide (46 mg, 1.1 mmol), and the mixture was stirred at rt for 4 h. To the reaction mixture was added 1 M HCl, and resultants were concentrated *in vacuo* to give carboxylic acid, which was used without further purification. To the carboxylic acid solution in MeOH-THF (1:1, 50 mL) was added 20% Pd(OH)₂/C (116 mg), and resulting mixture was stirred for 3 h under hydrogen (balloon). The reaction mixture was filtered through a pad of celite and the filtrate was concentrated *in vacuo* to give amino acid **13b**, which was used without further purification. To a solution of the crude amino acid **13b** in DMF-CH₂Cl₂ (1:2, 180 mL) was added DMAP (134 mg, 1.1 mmol), *Eti*-Pr₂N (187 μ L, 1.1 mmol), and DPPA (237 μ L, 1.1 mmol). The resulting mixture was stirred for 24 h at 90 °C under a nitrogen atmosphere. To the reaction mixture was added H₂O and the organic layer was extracted with EtOAc. The extracts were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified on silica gel (CHCl₃-EtOAc = 1:1) to give **14b** (194 mg, 40%, 3 steps). Spectral data for **14b**: [α]_D²⁵ -5.4 (*c* 0.63, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.51 (m, 2H), 8.25 (s, 1H), 8.22 (s, 1H), 8.18 (s, 2H) 5.44 (m, 1H), 5.35 (m, 1H), 4.58 (br, 2H), 3.07 (br, 4H), 2.74 (s, 3H), 2.68 (s, 3H), 2.23-1.84 (m, 4H), 1.57-1.17 (m, 26H); ¹³C NMR (400 MHz, CDCl₃) δ 164.8, 162.2, 160.0, 159.8, 156.0, 156.0, 155.9, 155.1, 154.6, 150.3, 150.1, 140.8, 140.6, 139.0, 138.3, 136.9, 136.6, 130.9, 129.6, 125.7,

124.6, 78.9, 47.7, 47.6, 40.3, 34.6, 31.9, 31.5, 29.6, 29.5, 28.4, 22.6, 21.9, 14.1, 11.8; HRMS (ESI, M+Na) calcd for C₄₂H₅₀N₁₀O₁₂Na 909.3507, found 909.3492.

Synthesis of 14a: To a solution of bis-trioxazole **12a** (1.5 g, 1.33 mmol) in THF-H₂O (3:1, 60 mL) was added lithium hydroxide (110 mg, 2.66 mmol), and the mixture was stirred at rt for 1 h. To the reaction mixture was added 1 M HCl, and resulting mixture was concentrated *in vacuo* to give carboxylic acid, which was used without further purification. To the carboxylic acid solution in MeOH-THF (1:1, 60 mL) was added Pd(OH)₂/C (250 mg), and resulting mixture was stirred for 2 h under a hydrogen atmosphere (balloon). The reaction mixture was filtered through a pad of celite and the filtrates were concentrated *in vacuo* to give amino acid **13a**. To a solution of the amino acid **13a** in DMF-CH₂Cl₂ (1:2, 400 mL) was added DMAP (650 mg, 5.32 mmol), *Eti*-Pr₂N (452 μ L, 2.66 mmol), and DPPA (1.15 mL, 5.32 mmol), and the resulting mixture was stirred at 90 °C for 3 h under a nitrogen atmosphere. To the reaction mixture was added H₂O and the organic layer was extracted with EtOAc. The extracts were washed with brine, dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue was purified on silica gel (CHCl₃-EtOAc = 3:1) to give **14a** (506 mg, 0.55 mmol, 41%, 3 steps). Spectral data for **14a**: [α]_D²⁵ +4.3 (*c* 2.1, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.44 (d, *J* = 7.5 Hz, 2H), 8.22 (s, 2H), 5.34 (m, 2H), 4.61 (br, 2H), 3.05 (m, 4H), 2.71 (s, 6H), 2.65 (s, 6H), 2.06 (m, 2H), 1.91 (m, 2H), 1.53-1.19 (m, 26H); ¹³C NMR (400 MHz, CDCl₃) δ 162.2, 160.0, 155.9, 155.0, 150.1, 149.9, 140.5, 136.6, 125.7, 124.6, 78.9, 47.4, 40.3, 34.6, 29.5, 28.3, 21.9, 11.7; HRMS (ESI, M+Na) calcd for C₄₄H₅₄N₁₀O₁₂Na 937.3820, found 937.3825.

Synthesis of 15b: To a solution of **14b** (130 mg, 0.146 mmol) in THF-MeOH (1:1, 20 mL) was added 12 M HCl (4 mL), and the mixture was stirred for 10 min at rt. The reaction mixture was concentrated *in vacuo* to give **15b** (95 mg, 86%). Spectral data for **15b**: [α]_D²⁵ -34.6 (*c* 2.6, MeOH); ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.13 (s, 1H), 9.11 (s, 1H), 8.92 (s, 1H), 8.89 (s, 1H), 8.31 (d, *J* = 7.3, 1H), 8.28 (d, *J* = 7.3, 1H), 7.78 (br 4H), 5.45 (m, 1H), 5.35 (m, 1H), 2.75 (s, 3H), 2.71 (s, 3H), 2.07 (m, 2H), 1.92 (m, 2H), 1.65-0.98 (m, 8H); ¹³C NMR (400 MHz, DMSO-*d*₆) δ 164.4, 162.0, 158.9, 158.7, 158.1, 157.8, 155.6, 155.6, 154.5, 154.5, 154.4, 151.4, 151.1, 142.5, 142.3, 141.8, 141.1, 136.0, 135.9, 129.7, 128.5, 124.7, 123.7, 69.8, 47.2, 47.1, 33.3, 26.7, 20.9, 11.5; HRMS (ESI, M+Na) calcd for C₃₂H₃₅N₁₀O₈Na 687.2639, found 687.2601.

Synthesis of 15a: To a solution of **14a** (270 mg, 0.295 mmol) in THF-MeOH (1:1, 10 mL) was added 12 M HCl (2 mL), and the mixture was stirred for 2 h at rt. The reaction mixture was concentrated *in vacuo* to give **15a** (200 mg, 86%). Spectral data for **15a**: [α]_D²⁵ +38.9 (*c* 0.5, MeOH); ¹H NMR (400 MHz,

DMSO- d_6) δ 8.89 (s, 2H), 8.24 (d, $J = 6.9$, 2H), 7.82 (br, 4H), 5.36 (br, 2H), 3.16 (br, 4H), 2.75 (br, 6H), 2.71 (br, 6H), 2.05 (br, 2H), 1.91 (br, 2H), 1.68-0.58 (m, 8H); ^{13}C NMR (400 MHz, DMSO- d_6) δ 162.0, 158.9, 158.1, 157.8, 155.6, 154.4, 151.3, 151.1, 142.3, 135.8, 124.7, 123.7, 48.6, 46.9, 45.6, 33.4, 26.7, 20.9, 11.5, 8.9; HRMS (ESI, M+Na) calcd for $\text{C}_{34}\text{H}_{39}\text{N}_{10}\text{O}_8$ 715.2952, found 715.2962.

Synthesis of L2A2-6M(2)OTD (**3b**): To a solution of **15b** (36 mg, 0.047 mmol) in acetic anhydride (4 mL) was added pyridine (1 mL), and the mixture was stirred at 40 °C for 15 h. The reaction mixture was concentrated *in vacuo*. The residue was purified on silica gel (EtOAc-MeOH = 4:1) to give L2A2-6M(2)OTD (**3b**) (33 mg, 91%). Spectral data for **3b**: $[\alpha]_D^{25} +30.9$ (c 1.5, MeOH); ^1H NMR (400 MHz, DMSO- d_6) δ 9.11 (s, 1H), 9.08 (s, 1H), 8.89 (s, 1H), 8.86 (s, 1H), 8.35 (d, $J = 7.5$ Hz, 1H), 8.31 (d, $J = 7.5$, 1H), 7.82 (br, 2H), 5.41 (dd, $J = 5.7, 12.6$ Hz, 1H), 5.32 (dd, $J = 5.2, 12.6$ Hz, 1H), 2.94 (br, 4H), 2.74 (s, 3H), 2.70 (s, 3H), 2.02 (br, 2H), 1.89 (br, 2H), 1.71 (s, 6H), 1.35-1.12 (m, 8H); ^{13}C NMR (400 MHz, DMSO- d_6) δ 170.3, 168.9, 164.6, 162.2, 158.9, 158.7, 155.7, 155.5, 154.5, 154.4, 151.3, 151.0, 142.5, 142.2, 141.7, 141.0, 136.0, 135.8, 129.7, 128.3, 124.6, 123.6, 69.8, 59.7, 47.3, 47.1, 38.3, 33.4, 28.7, 22.5, 21.4, 21.3, 20.7, 14.1, 11.5; HRMS (ESI, M+Na) calcd for $\text{C}_{36}\text{H}_{38}\text{N}_{10}\text{O}_{10}\text{Na}$ 793.2670, found 793.2687.

Synthesis of L2A2-6M(4)OTD (**3c**): To a solution of **15a** (16 mg, 0.022 mmol) in acetic anhydride (3 mL) was stirred at 40 °C for 7 h. The reaction mixture was concentrated *in vacuo* and the residue was purified on silica gel (EtOAc-MeOH = 4:1) to give L2A2-6M(4)OTD (**3c**) (17 mg, 97%). Spectral data for **3c**: $[\alpha]_D^{25} +7.0$ (c 0.5, MeOH); ^1H NMR (300 MHz, CDCl_3) δ 8.90 (s, 1H), 8.87 (s, 1H), 8.26 (br, 2H), 7.86 (br, 2H), 5.34 (br, 2H), 2.95 (br 4H), 2.73 (s, 6H), 2.69 (s, 6H), 2.02 (br, 2H), 1.89 (br, 2H), 1.73 (s, 6H), 1.36-1.10 (m, 8H); ^{13}C NMR (300 MHz, CDCl_3) δ 170.5, 162.7, 160.1, 156.0, 155.2, 150.3, 150.2, 140.7, 136.7, 125.5, 124.4, 47.2, 39.3, 34.2, 29.7, 28.6, 23.2, 21.8, 11.8, 11.7; HRMS (ESI, M+Na) calcd for $\text{C}_{38}\text{H}_{42}\text{N}_{10}\text{O}_{10}\text{Na}$ 821.2983, found 821.2982.

FRET melting assays: FRET melting assays were performed as previously reported methods.¹² The dual fluorescently labeled oligonucleotides were used in this protocol. The donor fluorophore was 6-carboxyfluorescein, FAM, and the acceptor fluorophore was 6-carboxytetramethylrhodamine, TAMRA. The oligonucleotides were initially dissolved as a 100 μM stock solution in MilliQ water; further dilutions were carried out in 60 mM potassium cacodylate buffer (pH 7.4). Dual-labeled DNA was denatured at a concentration of 0.4 μM by heating at 94 °C for 5 min followed by cooling to rt to anneal. We added the various concentrations of ligands (**3a-c**) into different samples, using a total reaction volume of 40 μL , with 0.2 μM of labelled oligonucleotide. Following experiments should keep the

temperature-procedure in real-time PCR and the procedure was finished as following: 25 °C for 10 minutes, then a stepwise increase of 1 °C every minute from 25 °C to reach 99 °C. During the procedures, the fluorescence of FAM was measured after each the temperature.

ACKNOWLEDGEMENTS

This work was supported in part by a Grant-in-Aid for Exploratory Research (21655060) and a grant under the Industrial Technology Research Grant Program (01A04006b) from the New Energy and Industrial Technology Development Organization (NEDO) of Japan. Dr. M.Tera and K. Iida are grateful for a JSPS Research Fellowship for Young Scientists.

REFERENCES AND NOTES

†We would like to dedicate this paper to Professor Dr. Albert Eschenmoser on the occasion of his 85th birthday.

1. For selected reviews see: (a) D. J. Patel, A. T. Phan, and V. Kuryavyi, *Nucleic Acids Research*, 2007, **35**, 7429; (b). S. Neidle, and G. N. Parkinson, *Biochimie*, 2008, **90**, 1184; (c). Y. Danzhou, and K. Okamoto, *Future Med. Chem*, 2010, **2**, 619-646.
2. Intramolecular telomeric G-quadruplex in sodium solution, see: (a) Y. Wang, and D. J. Patel, *Structure*, 1993, **1**, 263; Intramolecular telomeric G-quadruplex in potassium solution, see: (b) Y. Xu, Y. Noguchi, and H. Sugiyama, *Bioorg. Med. Chem.*, 2006, **14**, 5584; (c) A. Ambrus, D. Chen, J. Dai, T. Bialis, R. A. Jones, and D. Yang, *Nucleic Acids Res.*, 2006, **34**, 2723. (d) K. N. Luu, A. T. Phan, V. Kuryavyi, L. Lacroix, and D. J. Patel, *J. Am. Chem. Soc.*, 2006, **128**, 9963; (e) A. T. Phan, V. Kuryavyi, K. N. Luu, and D. J. Patel, *Nucleic Acids Res.*, 2007, **35**, 6517; Crystal structure of intramolecular telomeric G-quadruplex in the presence of potassium cation, see: (f) G. N. Parkinson, M. P. Lee, and S. Neidle, *Nature*, 2002, **417**, 876.
3. H. Tahara, K. Shin-ya, H. Seimiya, H. Yamada, T. Tsuruo, and T. Ide, *Oncogene*, 2006, **25**, 1955.
4. D. Gomez, T. Wenner, B. Brassart, C. Douarre, M.-F. O'Donohue, V. E. Khoury, K. Shin-ya, H. Morjani, C. Trantesaux, and J. F. Riou, *J. Biol. Chem.*, 2006, **281**, 38721.
5. G-Quadruplex structure of *c-kit* promoter region, see: (a) S. Rankin, A. P. Reszka, J. Huppert, M. Zloh, G. N. Parkinson, A. K. Todd, S. Ladame, S. Balasubramanian, and S. Neidle, *J. Am. Chem. Soc.*, 2005, **127**, 10584; For *c-kit* transcription, see: (b) M. Bejugam, S. Sewitz, P. S. Shirude, R. Rodriguez, R. Shahid, and S. Balasubramanian, *J. Am. Chem. Soc.*, 2007, **129**, 12926.
6. G-Quadruplex structure of *bcl-2* promoter region, see: (a) J. Dai, T. S. Dexheimer, D. Chen, M.

- Carver, A. Ambrus, R. A. Jones, and D. Yang, *J. Am. Chem. Soc.*, 2006, **128**, 1096; (b) For *bcl-2* transcription, see: X.-D. Wang, T.-M. Ou, Y.-J. Lu, Z. Li, Z. Xu, C. Xi, J.-H. Tan, S.-L. Huang, L.-K. An, D. Li, L.-Q. Gu, and Z.-S. Huang, *J. Med. Chem.*, 2010, **53**, 4390.
7. G-quadruplex structure of *c-myc* promoter region, see: (a) T. Simonsson, P. Pecinka1, and M. Kubista, *Nucleic Acids Res.*, 1998, **26**, 1167; For *c-myc* transcription, see: (b) A. Siddiqui-Jain, C. L. Grand, D. J. Bearss, and L. H. Hurley, *Proc. Natl. Acad. Sci. USA*, 2002, **99**, 11593.
 8. For selected reviews see: (a) A. Arora, N. Kumar, T. Agarwal, and S. Maiti, *FEBS Journal*, 2010, **277**, 1345; (b) T. Ou, Y. Lu, J. Tan, Z. Huang, K.-Y. Wong, and L. Gu, *ChemMedChem*, 2008, **3**, 690.
 9. Isolation of telomestatin, see: (a) K. Shin-ya, K. Wierzba, K. Matsuo, T. Ohtani, Y. Yamada, K. Furihata, Y. Hayakawa, and H. Seto, *J. Am. Chem. Soc.*, 2001, **123**, 1262; Total synthesis of telomestatin, see: (b) T. Doi, M. Yoshida, K. Shin-ya, and T. Takahashi, *Org. Lett.* 2006, **8**, 4165.
 10. Selected reports of telomestatin as G-quadruplex ligands, see: (a) M.-Y. Kim, H. Vankayalapati, K. Shin-ya, K. Wierzba, and L. H. Hurley, *J. Am. Chem. Soc.*, 2002, **124**, 2098; (b) F. Rosu, V. Gabelica, K. Shin-ya, and E. D. Pauw, *Chem. Commun.*, 2003, 2702; (c) E. M. Rezler, J. Seenisamy, S. Bashyam, M.-Y. Kim, E. White, W. D. Wilson, and L. H. Hurley, *J. Am. Chem. Soc.*, 2005, **127**, 9439; (d) P. Shirude, E. Gillies, S. Ladame, F. Godde, K. Shin-Ya, I. Huc, and S. Balasubramanian, *J. Am. Chem. Soc.*, 2007, **129**, 11890.
 11. (a) M. Tera, Y. Sohtome, H. Ishizuka, T. Doi, M. Takagi, K. Shin-ya, and K. Nagasawa, *Heterocycles*, 2006, **69**, 505; (b) M. Tera, H. Ishizuka, M. Takagi, M. Suganuma, K. Shin-ya, and K. Nagasawa, *Angew. Chem. Int. Ed.*, 2008, **47**, 5557; (c) M. Tera, K. Iida, H. Ishizuka, M. Takagi, M. Suganuma, T. Doi K. Shin-ya, and K. Nagasawa, *ChemBioChem*, 2009, **10**, 431; (d) K. Iida, M. Tera, T. Hirokawa, K. Shin-ya, and K. Nagasawa, *Chem. Commun.*, 2009, 6481; (e) K. Iida, M. Tera, T. Hirokawa, K. Shin-ya, and K. Nagasawa, *J. Nucleic Acids*, 2010, *in press*; (f) M. Tera, K. Iida, K. Ikebukuro, H. Seimiya, K. Shin-ya, and K. Nagasawa, *Org. Biomol. Chem.*, 2010, **8**, 2749.
 12. (a) A. D. Cian, L. Guittat, M. Kaiser, B. Sacca, S. Amrane, A. Bourdoncle, P. Alberti, M. P. Teulade-Fichou, L. Lacroix, and J. L. Mergny, *Methods*, 2007, **42**, 183; (b) J. L. Mergny, and J.-C. Maurizot, *ChemBioChem*, 2001, **2**, 124.
 13. M. Kunishima, C. Kawachi, F. Iwasaki, K. Terao, and S. Tani, *Tetrahedron Lett.*, 1999, **40**, 5327.
 14. (a) G. Burrell, J. M. Evans, G. E. Jones, and G. Stemp, *Tetrahedron Lett.*, 1990, **31**, 3649; (b) A. J. Phillips, Y. Uto, P. Wipf, M. J. Reno, and D. R. Williams, *Org. Lett.*, 2000, **2**, 1165.
 15. D. R. Williams, D. J. Lowder, Y. G. Gu, and D. A. Brooks, *Tetrahedron Lett.*, 1997, **38**, 331.
 16. In FRET melting assays, four representative single stranded G-quadruplex forming oligonucleotides (GFOs), i.e., telo21, kit22, bcl27 and myc22 conjugated with dyes at both 5' and 3' ends were used

in the presence of potassium cation. GFOs and double-stranded oligonucleotides used in this paper are as follows.

Oligomer name	Sequence
telo21	5'-FAM-[GGGTTAGGGTTAGGGTTAGGG]-TAMRA-3'
kit22	5'-FAM-[AGGGAGGGCGCTGGGAGGAGGG]-TAMRA-3'
bcl27	5'-FAM-[CGGGCGCGGGAGGAAGGGGGCGGGAGC]-TAMRA-3'
myc22	5'-FAM-[GAGGGTGGGGAGGGTGGGGAAG]-TAMRA-3'
ds26	5'-FAM-[TATAGCTATATTTTTTATAGCTATA]-TAMRA-3'